Udvalget for Humanmedicinske Lægemidler (CHMP) har konkluderet, at fordelene ved Actos til behandling af type 2- sukkersyge er større end risiciene.
The Committee for Medicinal products for Human Use (CHMP) decided that Actos’ s benefits are greater than its risks for the treatment of type 2 diabetes.